[Tocolysis with beta sympathomimetics alone or combined with the calcium antagonist verapamil? Influence of verapamil on the fetus].
In a retrospective study, patients who underwent tocolytic therapy by beta-mimetics were investigated. 308 received Fenoterol monotherapy (group A) and 163 a combination of Fenoterol with the calcium-antagonist Verapamil in a dosage-relation of 1/20 (group B). The review of 287 cardiotocograms showed a significant increase in the foetal heart rate in both groups by about 13% after 114 minutes (A) and 146 minutes (B). Although the diaplacental transfer of Fenoterol to the foetus is very small, a high percentage of foetuses showed an increase in heart rate (84.7% in A, 86% in B). There was a significantly longer duration of foetal tachycardia in group B. Both groups were not different in respect of perinatal mortality (5.4% in A, 5.2% in B), birth weight, APGAR score, and the reasons for paediatric care. The great difference in placental permeability for Fenoterol and Verapamil may cause a danger for the foetus. Since no reasonable improvements are seen, additional Verapamil therapy is not recommended.
D001034:Apgar Score; D001724:Birth Weight; D004562:Electrocardiography; D005260:Female; D005280:Fenoterol / Q000627:therapeutic use; D005333:Fetus / Q000187:drug effects*; D005860:Germany, West; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D007226:Infant Mortality; D007752:Obstetric Labor, Premature / Q000517:prevention & control*; D011247:Pregnancy; D012189:Retrospective Studies; D014700:Verapamil / Q000494:pharmacology* / Q000627:therapeutic use
D005280:Fenoterol; D014700:Verapamil
Tokolyse mit beta-Sympathikomimetika allein oder in Kombination mit dem Kalzium-antagonisten Verapamil? 2. Einfluss des Verapamil auf den Feten.